FOSUN PHARMA (02196) announced that on August 29, 2025, the company's controlling subsidiary Fosun Pharma Industry entered into a License Agreement with Akeso. Under the agreement, Fosun Pharma Industry has been granted by Akeso the exclusive rights to research, develop, manufacture, register and commercialize (1) the AC-201 molecule, and (2) any pharmaceutical products containing AC-201 as the active ingredient within the licensed territory (mainland China and Hong Kong and Macau regions of China) and field (for the diagnosis, prevention and treatment of human diseases). According to the terms, Fosun Pharma Industry will pay Akeso up to RMB 156 million (including upfront payment and milestone payments) for this license.

AC-201 is an oral small molecule JAK inhibitor independently developed by Akeso, primarily intended for autoimmune disease indications. As of the announcement date (August 29, 2025), AC-201's first indication (moderate to severe plaque psoriasis) has completed Phase II clinical trials in mainland China. Based on clinical trial data available to date, AC-201 has demonstrated favorable safety and tolerability profiles with no serious adverse events observed. The Phase II clinical trial data for moderate to severe plaque psoriasis showed positive results, with all three dose groups achieving primary endpoints and key secondary endpoints after 12 weeks of treatment.

This collaboration aims to fully leverage the Group's advantages in drug clinical development, registration, manufacturing and commercialization, further enrich the Group's product pipeline in the autoimmune field, and improve market positioning, thereby enhancing the Group's core competitiveness in this therapeutic area.